½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1596234

¼¼°èÀÇ ¸Á¸· Áúȯ Ä¡·á ½ÃÀå : ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Retinal Disorder Treatment Market by Type (Diabetic Retinopathy, Macular Degeneration), Dosage Form (Capsules & Tablets, Eye Drops, Eye Solutions), Distribution Channel - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 182 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¸Á¸· Áúȯ Ä¡·á(Retinal Disorder Treatment) ½ÃÀåÀº 2023³â 86¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 93¾ï 8,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, CAGR 8.94%·Î ¼ºÀåÇϸç 2030³â¿¡´Â 157¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸Á¸· Áúȯ Ä¡·á ½ÃÀåÀº ¿¬·É °ü·Ã Ȳ¹Ýº¯¼º, ´ç´¢º´¼º ¸Á¸·º´Áõ, ¸Á¸· ¹Ú¸® µî ¸Á¸·¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁúȯÀ» °ü¸®Çϱâ À§ÇÑ ´Ù¾çÇÑ Ä¡·á Àü·«À» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ Çʿ伺Àº Àα¸ °í·ÉÈ­¿Í ´ç´¢º´ ¹× °íÇ÷¾Ð ¹ß»ý·ü Áõ°¡¿¡ µû¸¥ ÀÌ·¯ÇÑ ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡¼­ ºñ·ÔµË´Ï´Ù. Ä¡·á¹ý¿¡´Â Ç× VEGF ÁÖ»ç, ·¹ÀÌÀú Ä¡·á, ¼ö¼ú °³ÀÔ°ú °°Àº ¾à¸®ÇÐÀû Ä¡·á¹ýÀÌ Æ÷ÇԵ˴ϴÙ. º´¿ø, ¾È°ú º´¿ø, ¿¬±¸¼Ò¿Í °°Àº ÀÇ·á ȯ°æÀ» ´ë»óÀ¸·Î Àû¿ë ¹üÀ§°¡ ±¤¹üÀ§ÇÕ´Ï´Ù. ƯÈ÷ À¯ÀüÀÚ Ä¡·á ¹× Áٱ⼼Æ÷ ¿¬±¸ ºÐ¾ß¿¡¼­ À¯¸ÁÇÑ ¼Ö·ç¼Ç°ú °á°ú¸¦ Á¦°øÇϴ ÷´Ü ±â¼ú·Î ÀÎÇØ ½ÃÀåÀÌ ¼ºÀåÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿µÇâ ¿äÀÎÀ¸·Î´Â ³ëÀÎ Àα¸ Áõ°¡, ±â¼ú ¹ßÀü, Á¶±â °³ÀÔ¿¡ ´ëÇÑ ÀÇ·á ¼­ºñ½º Á¦°øÀÚµéÀÇ ÀÎ½Ä Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. ÀáÀçÀûÀ¸·Î ¼öÀͼºÀÌ ³ôÀº ±âȸ´Â ¿ø°Ý ÀÇ·á ¼­ºñ½º¿Í ¿¹Ãø ºÐ¼® ¹× °³ÀÎ ¸ÂÃãÇü ÀǷḦ À§ÇÑ AIÀÇ ÅëÇÕ¿¡ ÀÖ½À´Ï´Ù. ±â¾÷Àº ¿¬±¸ °³¹ß¿¡ ÅõÀÚÇÏ°í, ºò µ¥ÀÌÅÍ ºÐ¼®À» È°¿ëÇϸç, Àü·«Àû ÆÄÆ®³Ê½ÊÀ» Çü¼ºÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ÀÌÁ¡À» È°¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº Ä¡·á ºñ¿ë, ±ÔÁ¦ Àå¾Ö¹°, Àú°³¹ß Áö¿ª¿¡¼­ÀÇ Á¦ÇÑµÈ Á¢±Ù¼º µîÀÇ ÇÑ°è°¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼÷·ÃµÈ ¾È°ú Àü¹®ÀÇ ºÎÁ·°ú ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÀÇ·á ÀÎÇÁ¶ó ºÎÁ·°ú °°Àº ¹®Á¦´Â ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀº ºñ¿ë È¿À²ÀûÀÎ Ä¡·á ¼Ö·ç¼Ç°ú °³¼±µÈ ¾à¹° Á¦Çü¿¡ ÃÊÁ¡À» ¸ÂÃ߸ç Áö¼ÓÀûÀÎ Çõ½ÅÀÇ Çʿ伺¿¡ µû¶ó ¿©ÀüÈ÷ ³ôÀº °æÀï·ÂÀ» À¯ÁöÇÏ°í ÀÖ½À´Ï´Ù. Çõ½ÅÀÌ ¹«¸£ÀÍÀº ºÐ¾ß¿¡´Â ºñħ½ÀÀû Ä¡·á ¹æ¹ý °³¹ß°ú ȯÀÚ ¼øÀÀµµ Çâ»óÀ» À§ÇÑ Çâ»óµÈ Àü´Þ ½Ã½ºÅÛÀÌ Æ÷ÇԵ˴ϴÙ. ½ÃÀåÀº ºü¸¥ ±â¼ú ÀûÀÀ¿¡ ÀÇÇØ ÀÚ¿¬ Áß½ÉÀÌ µÇ¾î Ä¡·á Æз¯´ÙÀÓÀÇ ½ÇÁúÀûÀÎ º¯È­·Î À̾îÁý´Ï´Ù. ¼º°øÀûÀΠŽ»öÀ» À§Çؼ­´Â ±â¾÷ÀÌ ¹Îø¼ºÀ» À¯ÁöÇÏ°í, ºÎ¹® °£ Çù¾÷À» ¿ì¼±½ÃÇϸç, ½ÅÁ¦Ç° °³¹ßÀ» À§ÇÑ °­·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎÀ» À¯ÁöÇØ¾ß ÇÕ´Ï´Ù. Àü¹ÝÀûÀ¸·Î ¸Á¸· Àå¾Ö Ä¡·á ¿µ¿ª¿¡¼­ ½ÃÀå °ü·Ã¼ºÀ» À¯ÁöÇÏ°í ºñÁî´Ï½º ¼ºÀåÀ» ´Þ¼ºÇϱâ À§Çؼ­´Â Àü·«Àû À̴ϼÅƼºê¸¦ »õ·Î¿î Æ®·»µå¿¡ ¸ÂÃß´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ¿¬µµ(2023³â) 86¾ï 2,000¸¸ ´Þ·¯
ÃßÁ¤¿¬µµ(2024³â) 93¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø¿¬µµ(2030³â) 157¾ï ´Þ·¯
CAGR(%) 8.94%

½ÃÀå ¿ªÇÐ : ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ¸Á¸· Áúȯ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ÀλçÀÌÆ® °ø°³

¸Á¸· Áúȯ Ä¡·á ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ȹµæÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆľÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¾ÈÁúȯÀÇ ¿¬±¸¿¡ ´ëÇÑ ±ÔÁ¦±â°üÀ¸·ÎºÎÅÍ ÀÚ±Ý Á¦°ø Áõ°¡
    • ¼¼°è ¸Á¸·ÁúȯÀÇ À¯º´·ü Áõ°¡
    • Ȳ¹Ýº¯¼º¿¡ µû¸¥ ³ëÀÎ Àα¸ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¿¬±¸°³¹ß¿¡ µå´Â ºñ¿ëÀÇ ³ôÀÌ
  • ½ÃÀå ±âȸ
    • Ä¡·á¿¡¼­ ±â¼ú Çõ½Å°ú Áøº¸
    • Àü·«Àû Á¦ÈÞ È®´ë¿Í ½ÅÁ¦Ç° »ó¾÷È­
  • ½ÃÀå °úÁ¦
    • ´« ÇÕº´ÁõÀÇ °¡´É¼º

Porter's Five Forces : ¸Á¸· Áúȯ Ä¡·á ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ºñÁî´Ï½º Á¶Á÷ÀÌ °æÀïÀû À§Ä¡¸¦ Æò°¡ÇÏ°í Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ý·ÐÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ÈûÀÇ ¿ªÇÐ °ü°è¸¦ Æò°¡ÇÏ°í »õ·Î¿î º¥Ã³ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °­Á¡À» È°¿ëÇÏ°í ¾àÁ¡À» ÇØ°áÇϸç ÀáÀçÀûÀÎ ¹®Á¦¸¦ ¹æÁöÇÏ¿© º¸´Ù ź·ÂÀûÀÎ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¸Á¸· Áúȯ Ä¡·á ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâÀ» ÆľÇ

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¸Á¸· Áúȯ Ä¡·á ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡, °æÁ¦, »çȸ, ±â¼ú, ¹ý·ü ¹× ȯ°æ ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ¿© ¼±Á¦ÀûÀÌ°í ¹Ì·¡ ÁöÇâÀûÀÎ ÀÇ»ç °áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¸Á¸· Áúȯ Ä¡·á ½ÃÀå °æÀï ±¸µµ ÆľÇ

¸Á¸· Áúȯ Ä¡·á ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü µîÀÇ ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï ¿ìÀ§¸¦ ÆľÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀå ÁýÁßµµ, ¼¼ºÐÈ­, ÅëÇÕ Ãß¼¼¸¦ °­Á¶ÇÏ¿© º¥´õ°¡ °æÀïÀÌ Ä¡¿­ÇØÁö´Â ȯ°æ¿¡¼­ ÀÔÁö¸¦ °­È­ÇÏ´Â Àü·«Àû °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¸Á¸· Áúȯ Ä¡·á ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¸Á¸· Áúȯ Ä¡·á ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î º¥´õ¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. 4°³ÀÇ »çºÐ¸éÀº °ø±Þ¾÷ü¸¦ ¸íÈ®ÇÏ°í Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© »ç¿ëÀÚ°¡ Àü·«Àû ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : ¸Á¸· Áúȯ Ä¡·á ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æ ã±â

¸Á¸· Áúȯġ·á ½ÃÀåÀÇ Àü·«ºÐ¼®Àº ±Û·Î¹ú ½ÃÀå ÀÔÁö °­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ È°¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖ´Â ½Ã½ºÅÛÀ» ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆľÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D È°µ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇÏ°í ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ ¹× ±ÔÁ¦ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø ¹× Àü·«Àû ±âȸ´Â?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¾È ÁúȯÀÇ Á¶»ç¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ÀÚ±Ý Á¦°øÀÌ Áõ°¡
      • ¸Á¸·ÁúȯÀÇ ÀÌȯÀ²Àº ¼¼°èÀûÀ¸·Î Áõ°¡
      • °í·ÉÀÚ Àα¸ Áõ°¡¿Í Ȳ¹Ý º¯¼ºÁõ
    • ¾ïÁ¦¿äÀÎ
      • ¿¬±¸°³¹ß È°µ¿¿¡ µå´Â ¸·´ëÇÑ ºñ¿ë
    • ±âȸ
      • ±â¼ú Çõ½Å°ú Ä¡·á¹ýÀÇ Áøº¸
      • Àü·«Àû Çù¾÷ È®´ë¿Í ½ÅÁ¦Ç°ÀÇ »óÇ°È­
    • °úÁ¦
      • ´« ÇÕº´ÁõÀÇ °¡´É¼º
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
    • ¹ýÀû
    • ȯ°æÀû

Á¦6Àå ¸Á¸· Áúȯ Ä¡·á ½ÃÀå : À¯Çüº°

  • ´ç´¢º´ ¸Á¸·Áõ
  • Ȳ¹Ý º¯¼º
    • °Ç¼ºÈ²¹Ýº¯¼º
    • ½À¼ºÈ²¹Ýº¯¼º

Á¦7Àå ¸Á¸· Áúȯ Ä¡·á ½ÃÀå : Á¦Çüº°

  • ĸ½¶°ú ÅÂºí¸´
  • ¾È¾à
  • ¾ÆÀÌ ¼Ö·ç¼Ç
  • Á©
  • ¿¬°í

Á¦8Àå ¸Á¸· Áúȯ Ä¡·á ½ÃÀå : À¯Åë ä³Îº°

  • º´¿ø ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • ¼Ò¸Å ¾à±¹

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ¸Á¸· Áúȯ Ä¡·á ½ÃÀå

  • ¾Æ¸£ÇîƼ³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾Æ ÅÂÆò¾çÀÇ ¸Á¸· Áúȯ Ä¡·á ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸Á¸· Áúȯ Ä¡·á ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍÅ°
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼® ¹× Ãßõ

±â¾÷ ¸ñ·Ï

  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • Apellis Pharmaceuticals, Inc.
  • Bausch&Lomb Incorporated
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Graybug Vision Inc.
  • Kubota Pharmaceutical Holdings Co., Ltd.
  • Novartis AG
  • ONL Therapeutics
  • Opthea
  • Oxford Biomedica PLC
  • Oxurion NV
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Spark Therapeutics, Inc.
LYJ

The Retinal Disorder Treatment Market was valued at USD 8.62 billion in 2023, expected to reach USD 9.38 billion in 2024, and is projected to grow at a CAGR of 8.94%, to USD 15.70 billion by 2030.

The retinal disorder treatment market encompasses a range of therapeutic strategies aimed at managing conditions affecting the retina, such as age-related macular degeneration, diabetic retinopathy, and retinal detachment. The necessity for these treatments stems from the increasing prevalence of these disorders, largely driven by an aging population and rising incidence of diabetes and hypertension. Treatments include pharmacologic therapies, such as anti-VEGF injections, laser treatments, and surgical interventions. The application scope is broad, targeting healthcare settings like hospitals, ophthalmology clinics, and research institutes. The market is poised for growth due to advancing technologies, particularly in gene therapy and stem cell research, offering promising solutions and outcomes. Key growth influencers include the rising geriatric population, technological advancements, and increased awareness among healthcare providers regarding early intervention. Potential lucrative opportunities lie in telemedicine services and the integration of AI for predictive analytics and personalized medicine. Companies can capitalize on these by investing in research and development, leveraging big data analytics, and forming strategic partnerships. However, limitations include high treatment costs, regulatory hurdles, and limited access in underdeveloped regions. Additionally, challenges such as a shortage of skilled ophthalmologists and insufficient healthcare infrastructure in emerging markets could impede growth. The market remains highly competitive with a need for continuous innovation, demanding a focus on cost-effective therapeutic solutions and improved drug formulations. Areas ripe for innovation include developing non-invasive treatment methodologies and enhanced delivery systems to improve patient compliance. The market is nature-driven by rapid technological adaptation, leading to substantial shifts in treatment paradigms. Successful navigation requires companies to remain agile, prioritize cross-sector collaborations, and maintain robust pipelines for new product development. Overall, aligning strategic initiatives with emerging trends will be vital for sustaining market relevance and achieving business growth in the retinal disorder treatment domain.

KEY MARKET STATISTICS
Base Year [2023] USD 8.62 billion
Estimated Year [2024] USD 9.38 billion
Forecast Year [2030] USD 15.70 billion
CAGR (%) 8.94%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Retinal Disorder Treatment Market

The Retinal Disorder Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing funding by regulatory bodies for research on ocular disorders
    • Increasing prevalence of retinal disorders globally
    • Rising elderly population coupled with macular degeneration
  • Market Restraints
    • High cost involved in research and development activities
  • Market Opportunities
    • Technological innovations and advancements in treatments
    • Growing strategic collaborations and commercialization of novel products
  • Market Challenges
    • Probable complications in the eye

Porter's Five Forces: A Strategic Tool for Navigating the Retinal Disorder Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Retinal Disorder Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Retinal Disorder Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Retinal Disorder Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Retinal Disorder Treatment Market

A detailed market share analysis in the Retinal Disorder Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Retinal Disorder Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Retinal Disorder Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Retinal Disorder Treatment Market

A strategic analysis of the Retinal Disorder Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Retinal Disorder Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abeona Therapeutics Inc., Apellis Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Bayer AG, F. Hoffmann-La Roche Ltd., Graybug Vision Inc., Kubota Pharmaceutical Holdings Co., Ltd., Novartis AG, ONL Therapeutics, Opthea, Oxford Biomedica PLC, Oxurion NV, Pfizer, Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co., Ltd., and Spark Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Retinal Disorder Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Diabetic Retinopathy and Macular Degeneration. The Macular Degeneration is further studied across Dry Macular Degeneration and Wet Macular Degeneration.
  • Based on Dosage Form, market is studied across Capsules & Tablets, Eye Drops, Eye Solutions, Gels, and Ointments.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing funding by regulatory bodies for research on ocular disorders
      • 5.1.1.2. Increasing prevalence of retinal disorders globally
      • 5.1.1.3. Rising elderly population coupled with macular degeneration
    • 5.1.2. Restraints
      • 5.1.2.1. High cost involved in research and development activities
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological innovations and advancements in treatments
      • 5.1.3.2. Growing strategic collaborations and commercialization of novel products
    • 5.1.4. Challenges
      • 5.1.4.1. Probable complications in the eye
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Retinal Disorder Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Diabetic Retinopathy
  • 6.3. Macular Degeneration
    • 6.3.1. Dry Macular Degeneration
    • 6.3.2. Wet Macular Degeneration

7. Retinal Disorder Treatment Market, by Dosage Form

  • 7.1. Introduction
  • 7.2. Capsules & Tablets
  • 7.3. Eye Drops
  • 7.4. Eye Solutions
  • 7.5. Gels
  • 7.6. Ointments

8. Retinal Disorder Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Americas Retinal Disorder Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Retinal Disorder Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Retinal Disorder Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Abeona Therapeutics Inc.
  • 3. Apellis Pharmaceuticals, Inc.
  • 4. Bausch & Lomb Incorporated
  • 5. Bayer AG
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Graybug Vision Inc.
  • 8. Kubota Pharmaceutical Holdings Co., Ltd.
  • 9. Novartis AG
  • 10. ONL Therapeutics
  • 11. Opthea
  • 12. Oxford Biomedica PLC
  • 13. Oxurion NV
  • 14. Pfizer, Inc.
  • 15. Regeneron Pharmaceuticals Inc.
  • 16. Santen Pharmaceutical Co., Ltd.
  • 17. Spark Therapeutics, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦